Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics, Inc. (NASDAQ: RLMD) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Relmada Therapeutics, Inc. (NASDAQ: RLMD) was downgraded by analysts at Mizuho from a "strong-buy" rating to a "hold" rating.
Relmada Therapeutics, Inc. (NASDAQ: RLMD) had its "market perform" rating re-affirmed by analysts at Leerink Partners. They now have a $1.00 price target on the stock, down previously from $10.00.
Relmada Therapeutics, Inc. (NASDAQ: RLMD) had its "neutral" rating re-affirmed by analysts at Mizuho. They now have a $1.00 price target on the stock, down previously from $23.00.